CXCL12 and breast carcinoma: These CXCR4 antagonists have potential as anticancer drugs for the treatment of breast cancer because they prevent the CXCR4 receptor from attaching to its ligand, SDF-1 [20], and therefore suppress tumor proliferation and metastasis.